AT
AirNexis Therapeutics, Inc.
SEC filingBiotechnology · Palo Alto, CA
Amount raised$62Msold at filing
Total offering$200M$138M still open
Investors in the raise13count reported to the SEC
FiledMar 9, 2026first sale Jan 9, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Anna ChenDirector
Colin WalshDirector
Evan CaplanDirector
James LiExecutive Officer, Director
Jill CarrollDirector
Maria FardisExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.